Document is current
Any future updates will be listed below
-
Authors
Czamara, Darina http://orcid.org/0000-0001-7381-904X
Dieckmann, Linda
Röh, Simone
Kraemer, Sarah
Rancourt, Rebecca C.
Sammallahti, Sara
Kajantie, Eero
Laivuori, Hannele
Eriksson, Johan G.
Räikkönen, Katri
Henrich, Wolfgang
Plagemann, Andreas
Binder, Elisabeth B.
Braun, Thorsten
Entringer, Sonja
-
Funding
Funding for this research was provided by:
deutsche forschungsgemeinschaft (BR2925/3-1,-2,-3, PL241/8-2,-3)
Max Planck Institute of Psychiatry
- License Information
-
More Information
Article History
Received: 28 June 2021
Accepted: 12 August 2021
First Online: 26 August 2021
Declarations
:
: The betamethasone study was approved by the Ethics Committee of the Charité - Universitätsmedizin, Berlin, Germany (EA2-149-07). The ITU research protocol has been approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District (reference number: 269/13/03/00/09). In both studies, participants signed a written informed consent form.
: Not applicable.
: Due to the sensitive nature of the patient data used in our study and consent, the data sets are not and cannot be made publicly available. An interested researcher can obtain a de-identified data set after approval from the Study Boards. Data requests may be subject to further review by the national register authority and by the ethical committees.
: EB is the coinventor of <i>FKBP5</i>: a novel target for antidepressant therapy, European Patent no. EP 1687443 B1, and receives a research grant from Böhringer Ingelheim for a collaboration on functional investigations of <i>FKBP5</i>. Otherwise, the authors declare that they have no competing interests.
